Eli Lilly and Company (NYSE:LLY) is Parkman Healthcare Partners LLC’s 7th Largest Position

Parkman Healthcare Partners LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 30.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 28,163 shares of the company’s stock after selling 12,221 shares during the period. Eli Lilly and Company comprises about 2.9% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 7th biggest position. Parkman Healthcare Partners LLC’s holdings in Eli Lilly and Company were worth $21,742,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of LLY. Norges Bank purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at $8,407,908,000. Proficio Capital Partners LLC lifted its position in shares of Eli Lilly and Company by 100,387.1% in the fourth quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company’s stock valued at $4,016,110,000 after acquiring an additional 5,197,038 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company’s stock worth $9,747,214,000 after acquiring an additional 2,012,129 shares during the period. Capital International Investors grew its position in shares of Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company’s stock worth $6,740,272,000 after purchasing an additional 1,645,222 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Eli Lilly and Company during the 4th quarter valued at approximately $1,240,653,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LLY. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Guggenheim reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Hsbc Global Res downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and dropped their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $1,002.80.

Eli Lilly and Company Stock Down 1.3%

Shares of NYSE:LLY opened at $745.86 on Wednesday. The firm has a market capitalization of $706.88 billion, a PE ratio of 63.69, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The business has a 50 day simple moving average of $804.15 and a two-hundred day simple moving average of $808.91. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the business posted $2.58 earnings per share. Eli Lilly and Company’s revenue was up 45.2% on a year-over-year basis. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. Eli Lilly and Company’s dividend payout ratio (DPR) is 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.